Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin trihydrate (equivalent: amoxicillin, qty mg) - capsule, hard - excipient ingredients: magnesium stearate; microcrystalline cellulose; iron oxide yellow; titanium dioxide; gelatin - treatment of the following infections due to susceptible strains of sensitive organisms: note: therapy should be guided by bacteriologic studies including sensitivity tests and by clinical response. amoxycillin, alone or in combination with another antibiotic, may be used in an emergency where the causative agent has yet to be identified. respiratory tract infections: (acute and chronic): h.influenzae; streptococcus; s.pneumoniae; staphylococcus, non-penicillinase producing; e.coli (see microbiology). urogenital infections (complicated and uncomplicated, acute and chronic) e.coli (see microbiology); p.mirabilis; s.faecalis. gonorrhoea (n.gonorrhoeae, non-penicillinase producing). skin and skin structure infections: staaphylococcus, non-penicillinase producing: streptococcus: e.coli (see microbiology). prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously ha

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 573.394 mg (equivalent: amoxicillin, qty 500 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate; patent blue v; carmoisine - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms:,note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results.,skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli. (see microbiology),respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli. (see microbiology),genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see microbioology), p.mirabilis and s.faecalis.,gonorrhoea: n.gonorrhoeae (non-penicillinase producing).,prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - amoxicillin trihydrate, quantity: 286.697 mg (equivalent: amoxicillin, qty 250 mg) - capsule, hard - excipient ingredients: microcrystalline cellulose; magnesium stearate; titanium dioxide; purified water; iron oxide yellow; gelatin; sodium lauryl sulfate; patent blue v; carmoisine - it is indicated for the treatment of the following infections due to susceptible strains of sensitive organisms:,note: therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however, in emergency cases where the causative organism has not been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results.,skin and skin structure: staphylococcus, non-penicillinase producing; streptococcus; e.coli. (see microbiology),respiratory (acute and chronic): h.influenzae, streptococcus; s.pneumoniae; staphylococcus, non-penicillinase-producing; e.coli. (see microbiology),genitourinary tract (complicated and uncomplicated, acute and chronic): e.coli (see microbioology), p.mirabilis and s.faecalis.,gonorrhoea: n.gonorrhoeae (non-penicillinase producing).,prophylaxis of endocarditis: amoxycillin may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with a prosthetic heart valve or those who have previously had endocarditis.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - flucloxacillin, quantity: 500 mg - capsule, hard - excipient ingredients: brilliant blue fcf; erythrosine; magnesium stearate; gelatin; sodium lauryl sulfate; titanium dioxide; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - flucloxacillin, quantity: 250 mg - capsule, hard - excipient ingredients: titanium dioxide; erythrosine; brilliant blue fcf; gelatin; magnesium stearate; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; purified water; shellac; ethanol absolute; ammonia; potassium hydroxide - for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections. indications include pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis. changes made as described in the letter of 30/4/1998 from jason borg

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - cefaclor monohydrate, quantity: 393.4 mg (equivalent: cefaclor, qty 375 mg) - tablet, modified release - excipient ingredients: mannitol; hypromellose; hyprolose; methacrylic acid copolymer; stearic acid; magnesium stearate; propylene glycol; purified talc; colour - indications as 16 december 1997: keflor cd is indicated for the treatment of the following types of infections caused by susceptible organisms, in adults and children aged 12 years or older: acute bronchitis and acute exacerbations of chronic bronchitis; upper respiratory infections, including pharyngitis, tonsillitis and acute bacterial sinusitis: community-acquired pneumonia of mild to moderate severity (excluding atypical pneumonia); symptomatic lower urinary tract infections, including cystisis; skin and skin structure infections. note 1. penicillin in the usual drug of choice in the treatment and prevention of streptoccocal infections, including the prophylaxis of rheumatic fever. keflor cd is generally effective in the eradication of streptococci from the oropharynx; however, substantial data establishing the efficacy of keflor cd in the subsequent prevention of rheumatic fever are not available. 2. bacteriological studies to determine the causative organism and its susceptibility to cefaclor should be

Australia - English - Department of Health (Therapeutic Goods Administration)

avallon pharmaceuticals pty ltd - cefalexin monohydrate, quantity: 550 mg (equivalent: cefalexin, qty 500 mg) - capsule, hard - excipient ingredients: lactose monohydrate; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; brilliant blue fcf; sunset yellow fcf; purified water; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. respiratory tract infections; strep. pneumoniae and group a b-haemolytic streptococci. although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. bacterial sinusitis: streptococci, strep. pneumoniae and staph. aureus (methicillin sensitive only). otitis media: strep. pneumoniae, staphylococci (methicillin sensitive only). skin and skin structure infections: staphylococci (methicillin sensitive only) and/or streptococci. genitourinary tract infections, including acute prostatitis: e.coli, p.mirabilis, and klebsiella sp. the effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and noumed cephalexin is not indicated in these conditions. note. appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to noumed cephalexin. renal function studies should be perfomed when indicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 542.4 mg (equivalent: dicloxacillin, qty 500 mg) - capsule, hard - excipient ingredients: titanium dioxide; purified water; magnesium stearate; gelatin; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 271.2 mg (equivalent: dicloxacillin, qty 250 mg) - capsule, hard - excipient ingredients: gelatin; purified water; titanium dioxide; colloidal anhydrous silica; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - dicloxacillin sodium, quantity: 542.4 mg (equivalent: dicloxacillin, qty 500 mg) - capsule, hard - excipient ingredients: titanium dioxide; purified water; magnesium stearate; gelatin; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of confirmed or suspected staphylococcal and other gram positive coccal infections, including skin and skin structure and wound infections, infected burns, cellulitis, osteomyelitis and pneumonia (note: benzylpenicillin is the drug of choice for the treatment of streptococcal pneumonia).,bacteriological studies should be performed to determine the causative organisms and their susceptibility to dicloxacillin. dicloxacillin has less intrinsic antibacterial activity and a narrower spectrum than benzylpenicillin. dicloxacillin should therefore not be used in infections due to organisms susceptible to benzylpenicillin.,important note: when it is judged necessary that treatment is initiated before definitive culture and sensitivity results are known, if the microbiology report later indicates that the infection is due to an organism other than a benzylpenicillin resistant staphylococcus sensitive to dicloxacillin, the physician is advised to continue therapy with a drug other than dicloxacillin or any other penicillinase-resistant penicillin